Calviri provides cancer treatment products by combining the immunogenic source of neoantigens with a peptide array platform.
Calviri has raised $785K in total funding. The most recent round was Undisclosed. The last funding was announced in November 2024.
Calviri's investors include Mitzi Krockover, Jacque J. Sokolov.
Calviri is headquartered in Tempe, United States.
Calviri provides cancer treatment products by combining the immunogenic source of neoantigens with a peptide array platform.
Calviri is at the Undisclosed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Calviri — Funding & Investors." VCBacked, November 8, 2024, https://www.vcbacked.co/company/calviri. Accessed August 14, 2026.
VCBacked. (2024). Calviri — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/calviri
{{cite web |title=Calviri — Funding & Investors |url=https://www.vcbacked.co/company/calviri |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated